Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers
Brandon M. Huffman(Dana-Farber Cancer Institute), Samuel J. Klempner(Massachusetts General Hospital), Adham Jurdi(University of the Incarnate Word), Farshid Dayyani, Vasily N. Aushev(Natera (United States)), Meenakshi Malhotra(Stanford University), Giby V. George(Pancreatic Cancer Action Network), Gregory P. Botta(Moores Cancer Center), Steven B. Maron(Memorial Sloan Kettering Cancer Center), Alexey Aleshin(Natera (United States)), Griffin Budde(Natera (United States)), Shifra Krinshpun(Natera (United States)), Pashtoon Murtaza Kasi(Cornell University), Daniel V.T. Catenacci(University of Illinois Chicago), Shruti Sharma(Natera (United States)), Joseph Chao(City of Hope), Diana L. Hanna(University of Southern California), Solomon Moshkevich(Natera (United States))
Cited by 72
Related Papers
Colorectal cancer
|The Lancet|2019|5k
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.3k
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
|JAMA Oncology|2019|992
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603